These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12718459)

  • 1. Gender differences in secondary prevention of coronary heart disease: reasons to worry or not?
    Nilsson P; Brandström H; Lingfors H; Erhardt L; Hedbäck B; Israelsson B; Sjöberg G;
    Scand J Prim Health Care; 2003 Mar; 21(1):37-42. PubMed ID: 12718459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical treatment and secondary prevention of coronary heart disease in general practice in Iceland.
    Sigurdsson EL; Jónsson JS; Thorgeirsson G
    Scand J Prim Health Care; 2002 Mar; 20(1):10-5. PubMed ID: 12086276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence on lifestyle measures and five-year coronary risk by a comprehensive lifestyle intervention programme in patients with coronary heart disease.
    Vestfold Heartcare Study Group
    Eur J Cardiovasc Prev Rehabil; 2003 Dec; 10(6):429-37. PubMed ID: 14671465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Secondary Prevention among Coronary Heart Disease Patients in a High-Risk Region in Finland.
    Repo T; Tykkyläinen M; Mustonen J; Rissanen TT; Ketonen M; Toivakka M; Laatikainen T
    Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29641497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).
    Bowker TJ; Clayton TC; Ingham J; McLennan NR; Hobson HL; Pyke SD; Schofield B; Wood DA
    Heart; 1996 Apr; 75(4):334-42. PubMed ID: 8705756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of diet and physical exercise intervention programmes on coronary heart disease risk in smoking and non-smoking men in Sweden.
    Näslund GK; Fredrikson M; Hellénius ML; de Faire U
    J Epidemiol Community Health; 1996 Apr; 50(2):131-6. PubMed ID: 8762375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR).
    Gudbjörnsdottir S; Eeg-Olofsson K; Cederholm J; Zethelius B; Eliasson B; Nilsson PM;
    Diabet Med; 2009 Jan; 26(1):53-60. PubMed ID: 19125761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of postal prompts to patients and general practitioners on the quality of primary care after a coronary event (POST): randomised controlled trial.
    Feder G; Griffiths C; Eldridge S; Spence M
    BMJ; 1999 Jun; 318(7197):1522-6. PubMed ID: 10356008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial.
    Wood DA; Kotseva K; Connolly S; Jennings C; Mead A; Jones J; Holden A; De Bacquer D; Collier T; De Backer G; Faergeman O;
    Lancet; 2008 Jun; 371(9629):1999-2012. PubMed ID: 18555911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
    Hay JW; Sterling KL
    Pharmacoeconomics; 2005; 23(2):133-41. PubMed ID: 15748088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential population impact of the UK government strategy for reducing the burden of coronary heart disease in England: comparing primary and secondary prevention strategies.
    Gemmell I; Heller RF; Payne K; Edwards R; Roland M; Durrington P
    Qual Saf Health Care; 2006 Oct; 15(5):339-43. PubMed ID: 17074870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
    Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
    Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.
    Kotseva K; Wood D; De Backer G; De Bacquer D; Pyörälä K; Keil U;
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):121-37. PubMed ID: 19287307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Secondary prevention of coronary disease--at the turn of the millennium in light of the Hungarian data of the EUROASPIRE I-II. Studies].
    Ostör E; Jánosi A; Adám Z; Bárczy G; Borbás S; Dávid B; Gallai I; Podmaniczky M; Ruzsányi T
    Orv Hetil; 2003 Dec; 144(49):2399-404. PubMed ID: 14725205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of inequalities in secondary prevention of coronary heart disease in a universal coverage health care system.
    Munoz MA; Rohlfs I; Masuet S; Rebato C; Cabañero M; Marrugat J;
    Eur J Public Health; 2006 Aug; 16(4):361-7. PubMed ID: 16230314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of medication use in a multicomponent intervention: results from the WISEWOMAN program.
    Khavjou OA; Finkelstein EA; Will JC
    Am J Health Promot; 2007; 21(4):267-73. PubMed ID: 17375493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of interventions to reduce coronary heart disease risk.
    Adedeji OO; Oyakhire GK; Saeed AK; Ghamdi AI
    West Afr J Med; 2011; 30(3):197-201. PubMed ID: 22120486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
    Coukell AJ; Wilde MI
    Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.